SecBot SecBot

MESO drug pipeline

MESOBLAST LTD · 2 rated drugs
$12.45
−6.2% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3 / Filed BLA
Time to marketLVAD/heart failure BLA now under FDA review with modular review requested — no PDUFA date set yet (potentially 2027 if accepted). CLBP indication likely 2028 at earliest (topline mid-2027, BLA Q3 2027, FDA action 2028).

rexlemestrocel-L Updated Jul 3

What to watch

Mesoblast just filed a BLA for rexlemestrocel-L in LVAD/heart failure, the next catalyst is FDA acceptance and a PDUFA date. Meanwhile, the much larger CLBP opportunity (7M+ US patients, non-opioid approach) is advancing with Phase 3 enrollment complete and topline due mid-2027. The company already generates real revenue from Ryoncil (~$110-120M FY2026 guidance), de-risking the story vs. pre-revenue biotechs. Monitor (1) FDA's action on the LVAD BLA modular review, (2) CLBP Phase 3 topline in mid-2027, and (3) Ryoncil revenue growth trajectory.

Bull case
  • BLA for LVAD/heart failure just filed with FDA (June 30, 2026), and RMAT designation enables accelerated/priority review, a potentially faster path to market
  • DREAM-HF Phase 3 data showed up to 60% reduction in cardiovascular death in heart failure patients with inflammation (published in JACC, peer-reviewed)
  • CLBP Phase 3 enrollment completed April 2026, addresses a $10B+ market with 7M+ US patients as a non-opioid treatment; FDA has confirmed 12-month pain reduction as an approvable endpoint
Bear case
  • DREAM-HF Phase 3 trial failed its primary endpoint (heart failure hospitalizations); only showed mortality benefit in subgroups, this weakens the clinical package
  • LVAD BLA uses a modular review process, which is non-standard and carries timeline uncertainty, no PDUFA date set
  • Manufacturing and CMC (chemistry, manufacturing, controls) complexity for cell therapies is a common source of FDA delays and CRLs
● neutral
Impact
PhaseApproved
Time to marketAlready on the market — FDA-approved December 18, 2024, commercially launched in the US from March 2025.

Ryoncil remestemcel-L-rknd Updated Jul 9

What to watch

Ryoncil is already delivering real revenue ($110-120M annualized) but the stock also carries very high short interest (~83% short ratio). Watch quarterly revenue growth trajectory and gross margins as the proxy for commercial success; the next true binary catalysts are 12+ months away from other pipeline drugs. Recent insider buying from director George Gregory and institutional accumulation (Bank of America, UBS, BlackRock) provide some confidence in the commercial trajectory.

Bull case
  • First-and-only FDA-approved MSC therapy in the US, no direct competitor in pediatric SR-aGvHD, giving it a regulatory moat.
  • Strong commercial launch: ~$115M net revenue in FY2026 with 93% gross margins, approaching a ~$140M annualized run-rate by Q4 2026 ($36M net in June quarter).
  • Massive label expansion opportunity: the adult SR-aGvHD market is 3-4x larger than pediatric per management, with a pivotal trial already underway.
Bear case
  • The defining binary catalyst (FDA approval) has already passed, no imminent regulatory decision for Ryoncil to re-rate the stock.
  • Extremely high short interest: 14-day avg short ratio of ~83.4%, signaling heavy bearish positioning that could reflect skepticism on revenue sustainability or valuation.
  • Competition from ruxolitinib (Jakafi, Incyte), already approved for SR-aGvHD in patients >12 years, though Ryoncil is the only approved option for pediatric patients.